Sleeping through the storm: Preventing myelosuppression with quizartinib

Oncotarget. 2017 Sep 30;8(51):88255-88256. doi: 10.18632/oncotarget.21395. eCollection 2017 Oct 24.

Authors

Samuel J Taylor¹, Wallace Y Langdon¹

Affiliation

¹ Wallace Y. Langdon: School of Biomedical Sciences, University of Western Australia, Crawley, Western Australia, Australia.

No abstract available

Keywords: FLT3 inhibitors; chemotherapy; hematopoietic progenitors; myelosuppression; quizartinib.

Publication types

Editorial